PUBLISHER: Renub Research | PRODUCT CODE: 1185048
PUBLISHER: Renub Research | PRODUCT CODE: 1185048
China Vaccine Market, Size, Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
China Vaccine Market will surpass US$ 12.16 Billion by 2027 at a CAGR of 11.97 Percent according to Renub Research. Annually in China, approx. 700 million vaccine doses are produced; China is one of the world's largest producers of vaccines. As a result, China has drawn significant attention to the vaccine industry to play a representative role. In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
Category 1 & 2 Vaccines in China
In China, Vaccines are available through the government's Expanded Program on Immunization (EPI) at no charge for aged 14 years of children. These government-purchased vaccines are called Category 1 under the Regulations on the Administration of Vaccines and Vaccination. In contrast, private-sector also known as Category 2 vaccines, such as rabies vaccine, influenza vaccine (InfV), and Haemophilus influenza type b vaccine (Hib), are available but are usually paid for out-of-pocket, as they are included in neither the EPI system nor government health insurance. According to our research findings, the China Vaccine market was US$ 6.91 Billion in 2022.
Disease Type: Pneumococcal, Meningococcal Meningitis, and DTP Vaccines Controls Significant Portion of China Vaccines Industry
Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market. The vaccine market in China is segmented into Meningococcal meningitis, Pneumococcal, DTP, Ebola, Rabies & Others. In Aug 2021, China formally revised its laws to allow parents to have up to three children to boost the birth rate. In part, thanks to the loosening of the second-child policy in China, the number is expected to increase. China's vaccine industry has always been more petite and less mature than it's US, European, or Indian counterparts. However, over the past decades, it has rapidly grown to become one of the only developing countries able to manufacture and supply most vaccines used in its domestic immunization program.
Product Insight: PCV13 has Highest Share in the Chinese Vaccine Industry
In terms of products, the Products included in this report are as follows: MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, and PPV23. PCV13 holds the maximum share of the China vaccine market. Therefore, it is predicted that PCV13 will also maintain its top place during the forecasting period. In addition, China is the most prominent vaccine consumer in the world. As a result, Chinese residents have become much more aware of preventive health care due to its impact, which has also driven the vaccination rate.
Key Company Insights
The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd. In addition, the R&D, clinical, and commercialization experience accumulated by the COVID-19 vaccine would help a group of outstanding domestic Chinese vaccine company's snowball. Against this backdrop, the Chinese vaccine industry is expected to usher in a golden period. The next decade will be for China's biopharmaceuticals to move from catching up to surpassing a 'golden decade' for the Chinese vaccine industry.
May 2022, Walvax Biotechnology Co., Ltd. announced the results for the immunogenicity and safety profile of PCV13, the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, administered as an infant series at 3, 4, and 5 months of age and a booster dose at 12-15 months of age in Chinese infants as part of the randomized, multi-center, double-blind, and positive-controlled phase 3 clinical trial in China to demonstrate the non-inferior immune responses and safety of PCV13 as compared to Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein] ("PCV7").
Renub Research report titled "China Vaccine Market & Doses Forecast By Sector (Private, Public), Disease Type (Meningococcal Meningitis, Pneumococcal, DTP, Ebola, Rabies, Others), Products (MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, PPV23, Others), Company (Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.)" provides a complete analysis of China Vaccine Market.
Sectors - Vaccine Market & Doses in China
- Public
- Private
Diseases -
1. Meningococcal Meningitis
2. Pneumococcal
3. DTP
4. Ebola
5. Rabies
6. Others
Products -
1. MCV4
2. MPSV4
3. MCV2-Hib
4. MCV2
5. MPSV2 and Men A
6. PCV13
7. PPV23
All the companies covered in the report has been covered from the following points
- Overview
- Recent Development
- Vaccine Pipeline
- Revenue Analysis
Key Company Covered
1. Sinopharm Group (China National Biotec Group Company Limited)
2. Hualan Biological Engineering Inc
3. Chongqing Zhifei Biological Products Co Ltd
4. Walvax Biotechnology Co Ltd
5. Beijing Tiantan Biological Products Corp Ltd
6. Sinovac Biotech
7. Shenzhen Kangtai Biological Products Co Ltd
Table of Contents
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 4.3 Opportunities
5. China Vaccine Market
- 5.1 Public
- 5.2 Private
6. China Vaccine Doses
- 6.1 Public
- 6.2 Private
7. China Vaccine Share Analysis
- 7.1 By Sectors Market Share
- 7.2 By Sectors Vaccine Doses Share
- 7.3 By Products Type Market Share
- 7.4 By Disease Type Market Share
8. Meningococcal Meningitis Vaccine Market & Doses Analysis
- 8.1 Meningococcal Meningitis Vaccine
- 8.1.1 Public
- 8.1.2 Private
- 8.2 Meningococcal Meningitis Doses
- 8.2.1 Public
- 8.2.2 Private
9. Pneumococcal Vaccines Market & Doses Analysis
- 9.1 Pneumococcal Vaccines
- 9.2 Pneumococcal Vaccines Doses
10. DTP Vaccine Market & Doses Analysis
- 10.1 DTP Vaccine Market
- 10.1.1 DTaP
- 10.1.2 DTcP
- 10.2 DTP Vaccine Doses
- 10.2.1 Public
- 10.2.2 Private
11. Rabies Vaccine Market
12. Ebola Vaccine Market
13. Product - China Vaccine Market
- 13.1 MCV4
- 13.2 MPSV4
- 13.3 MCV2-Hib
- 13.4 MCV2
- 13.5 MPSV2 and Men A
- 13.6 PCV13
- 13.7 PPV23
- 13.8 Others
14. The Vaccine Regulatory Authority of China
15. Required and Recommended Vaccinations for China Travel
16. Mergers & Acquisitions
17. Company Sales
- 17.1 Sinopharm Group (China National Biotec Group Company Limited)
- 17.1.1 Overview
- 17.1.2 Recent Initiatives
- 17.1.3 Net Sales
- 17.2 Hualan Biological Engineering Inc
- 17.2.1 Overview
- 17.2.2 Recent Initiatives
- 17.2.3 Net Sales
- 17.3 Chongqing Zhifei Biological Products Co Ltd
- 17.3.1 Overview
- 17.3.2 Recent Initiatives
- 17.3.3 Net Sales
- 17.4 Walvax Biotechnology Co Ltd
- 17.4.1 Overview
- 17.4.2 Recent Initiatives
- 17.4.3 Net Sales
- 17.5 Beijing Tiantan Biological Products Corp Ltd
- 17.5.1 Overview
- 17.5.2 Recent Initiatives
- 17.5.3 Net Sales
- 17.6 Sinovac Biotech
- 17.6.1 Overview
- 17.6.2 Recent Initiatives
- 17.6.3 Net Sales
- 17.7 Shenzhen Kangtai Biological Products Co Ltd
- 17.7.1 Overview
- 17.7.2 Recent Initiatives
- 17.7.3 Net Sales
List of Figures
- Figure-01: China - Public Vaccine Market (Million US$), 2017 - 2022
- Figure-02: China - Forecast for Public Vaccine Market (Million US$), 2023 - 2027
- Figure-03: China - Private Vaccine Market (Million US$), 2017 - 2022
- Figure-04: China - Forecast for Private Vaccine Market (Million US$), 2023 - 2027
- Figure-05: China - Public Vaccine Doses (Million), 2017 - 2022
- Figure-06: China - Forecast for Public Vaccine Doses (Million), 2023 - 2027
- Figure-07: China - Private Vaccine Doses (Million), 2017 - 2022
- Figure-08: China - Forecast for Private Vaccine Doses (Million), 2023 - 2027
- Figure-09: Public - Meningococcal Meningitis Vaccine Market (Million US$), 2017 - 2022
- Figure-10: Public - Forecast for Meningococcal Meningitis Vaccine Market (Million US$), 2023 - 2027
- Figure-11: Private - Meningococcal Meningitis Vaccine Market (Million US$), 2017 - 2022
- Figure-12: Private - Forecast for Meningococcal Meningitis Vaccine Market (Million US$), 2023 - 2027
- Figure-13: Public - Meningococcal Meningitis Vaccine Doses (Million), 2017 - 2022
- Figure-14: Public - Forecast for Meningococcal Meningitis Vaccine Doses (Million), 2023 - 2027
- Figure-15: Private - Meningococcal Meningitis Vaccine Doses (Million), 2017 - 2022
- Figure-16: Private - Forecast for Meningococcal Meningitis Vaccine Doses (Million), 2023 - 2027
- Figure-17: China - Pneumococcal Vaccines Market (Million US$), 2017 - 2022
- Figure-18: China - Forecast for Pneumococcal Vaccines Market (Million US$), 2023 - 2027
- Figure-19: China - Pneumococcal Vaccines Doses Doses (Million), 2017 - 2022
- Figure-20: China - Forecast for Pneumococcal Vaccines Doses Doses (Million), 2023 - 2027
- Figure-21: China - DTP Vaccine Market (Million US$), 2017 - 2022
- Figure-22: China - Forecast for DTP Vaccine Market (Million US$), 2023 - 2027
- Figure-23: China - DTaP Vaccine Market Market (Million US$), 2017 - 2022
- Figure-24: China - Forecast for DTaP Vaccine Market Market (Million US$), 2023 - 2027
- Figure-25: China - DTcP Vaccine Market Market (Million US$), 2017 - 2022
- Figure-26: China - Forecast for DTcP Vaccine Market Market (Million US$), 2023 - 2027
- Figure-27: DTP - Public Vaccine Doses (Million), 2017 - 2022
- Figure-28: DTP - Forecast for Public Vaccine Doses (Million), 2023 - 2027
- Figure-29: DTP - Private Vaccine Doses (Million), 2017 - 2022
- Figure-30: DTP - Forecast for Private Vaccine Doses (Million), 2023 - 2027
- Figure-31: China - Rabies Vaccine Market (Million US$), 2017 - 2022
- Figure-32: China - Forecast for Rabies Vaccine Market (Million US$), 2023 - 2027
- Figure-33: China - Ebola Vaccine Market (Million US$), 2018 - 2022
- Figure-34: China - Forecast for Ebola Vaccine Market (Million US$), 2023 - 2027
- Figure-35: Product - MCV4 Vaccine Market (Million US$), 2020 - 2022
- Figure-36: Product - Forecast for MCV4 Vaccine Market (Million US$), 2023 - 2027
- Figure-37: Product - MPSV4 Vaccine Market (Million US$), 2017 - 2022
- Figure-38: Product - Forecast for MPSV4 Vaccine Market (Million US$), 2023 - 2027
- Figure-39: Product - MCV2-Hib Vaccine Market (Million US$), 2017 - 2022
- Figure-40: Product - Forecast for MCV2-Hib Vaccine Market (Million US$), 2023 - 2027
- Figure-41: Product - MCV2 Vaccine Market (Million US$), 2017 - 2022
- Figure-42: Product - Forecast for MCV2 Vaccine Market (Million US$), 2023 - 2027
- Figure-43: Product - MPSV2 and Men A Vaccine Market (Million US$), 2017 - 2022
- Figure-44: Product - Forecast for MPSV2 and Men A Vaccine Market (Million US$), 2023 - 2027
- Figure-45: Product - PCV13 Vaccine Market (Million US$), 2017 - 2022
- Figure-46: Product - Forecast for PCV13 Vaccine Market (Million US$), 2023 - 2027
- Figure-47: Product - PPV23 Vaccine Market (Million US$), 2017 - 2022
- Figure-48: Product - Forecast for PPV23 Vaccine Market (Million US$), 2023 - 2027
- Figure-49: Product - Others Vaccine Market (Million US$), 2017 - 2022
- Figure-50: Product - Forecast for Others Vaccine Market (Million US$), 2023 - 2027
- Figure-51: Sinopharm Group (China National Biotec Group Company Limited) - Global Revenue (Billion US$), 2017 - 2022
- Figure-52: Sinopharm Group (China National Biotec Group Company Limited) - Forecast for Global Revenue (Billion US$), 2023 - 2027
- Figure-53: Hualan Biological Engineering Inc - Global Revenue (Million US$), 2017 - 2022
- Figure-54: Hualan Biological Engineering Inc - Forecast for Global Revenue (Million US$), 2023 - 2027
- Figure-55: Chongqing Zhifei Biological Products Co Ltd - Global Revenue (Million US$), 2017 - 2022
- Figure-56: Chongqing Zhifei Biological Products Co Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
- Figure-57: Walvax Biotechnology Co Ltd - Global Revenue (Million US$), 2017 - 2022
- Figure-58: Walvax Biotechnology Co Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
- Figure-59: Beijing Tiantan Biological Products Corp Ltd - Global Revenue (Million US$), 2017 - 2022
- Figure-60: Beijing Tiantan Biological Products Corp Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
- Figure-61: Sinovac Biotech - Global Revenue (Million US$), 2017 - 2022
- Figure-62: Sinovac Biotech - Forecast for Global Revenue (Million US$), 2023 - 2027
- Figure-63: Shenzhen Kangtai Biological Products Co Ltd - Global Revenue (Million US$), 2017 - 2022
- Figure-64: Shenzhen Kangtai Biological Products Co Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
List of Tables
- Table-01: China - Vaccine Market Share by Sectors (Percent), 2017 - 2021
- Table-02: China - Forecast for Vaccine Market Share by Sectors (Percent), 2022 - 2027
- Table-03: China - Vaccine Doses Share by Sectors (Percent), 2017 - 2021
- Table-04: China - Forecast for Vaccine Doses Share by Sectors (Percent), 2022 - 2027
- Table-05: China - Vaccine Market Share by Products Type (Percent), 2017 - 2021
- Table-06: China - Forecast for Vaccine Market Share by Products Type (Percent), 2022 - 2027
- Table-07: China - Vaccine Market Share by Disease Type (Percent), 2017 - 2021
- Table-08: China - Forecast for Vaccine Market Share by Disease Type (Percent), 2022 - 2027
